20210526 post AG EN
Year: 2021
Transgene reports business update and end Q1 2021 financial position
20210427 – Transgene – Q1 Financial update EN
Transgene Announces Upcoming Investor Meetings
20210412 – Transgene investor agenda EN
Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation
Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
20210409 – TG6002 AACR EN
Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
20210407 document AG EN
Availability of Transgene’s 2020 Universal Registration Document
20210401 Transgene mise a disposition ddr 2020 EN
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Tengku Ibrahim Maulana, et al. Adv Drug Deliv Rev., March 30 2021 – Read the article Publication
Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
20210310 Transgene TG4001 randomized Phase II EN
Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
20210310 Transgene Results 2020 EN